ChinaBio® Today Articles

Welcome to the ChinaBio® Today store. As a service to our readers, we offer access to individual articles for only $5.00 (USD) each.  Of course, a subscription is only $20/mo, so you may prefer to subscribe.  If so, click on Subscribe in the menu.

Browse


All Products

Viewing 1771 - 1785 of 5996 products
CARsgen Granted US Orphan Drug Status for Claudin18.2 CAR-T Drug
$5.00
Available
I-Mab to Start China Phase III Trial of Long-Acting Treatment for Dwarfism
$5.00
Available
Virogin Raises $62 Million for Oncolytic Virus Portfolio
$5.00
Available
Sumgen Completes $32 Million Round for Immunotherapy Antibodies
$5.00
Available
CStone Out-licenses China Rights for PD-1 to Pfizer in $480 Million Deal
$5.00
Available
Fosun Closes $182 Million In-licensing of Polyphor Cancer Treatment
$5.00
Available
Apollomics to Start China Trials of In-Licensed Leukemia Drug
$5.00
Available
Taimei Tech Completes $176 Million Raise for AI Clinical Trial Software
$5.00
Available
BioShin Raises $60 Million to Bring Biohaven's Drugs to China
$5.00
Available
Junshi Says its PD-1 Effective Against Nasopharyngeal Carcinoma
$5.00
Available
Zai Lab Raises $761 Million in Hong Kong IPO; Climbs 8.5% Higher
$5.00
Available
InventisBio Completes $147 Million Round for Small-Molecule Drugs
$5.00
Available
Bioray Lab Starts Tests of Gene Edited PD1-Knockin CAR-T Candidate
$5.00
Available
Sperogenix Acquires China Rights to Rare Disease Candidate in $78 Million Deal
$5.00
Available
BioDuro and Sundia Merge to Form China-US CRDMO Backed by Advent
$5.00
Available